E-mail: radocha@fnhk.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- BETTER TREATMENT RESPONSE IS ASSOCIATED WITH LENALIDOMIDE 25 MG ONCE-DAILY VS. 25 MG EVERY-OTHER-DAY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
- Bortezomib (Velcade) in the Treatment of Relapsed or Refractory Multiple Myeloma: Analysis of Safety and Efficacy of Bortezomib From Registry of Monoclonal Gammopathy of Czech Myeloma Group
- COMPLEX KARYOTYPE CHANGES ARE THE STRONGEST PREDICTOR OF OUTCOME OF ALLOGENEIC TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
- Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation.
- Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic
- EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELOMA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC
- IDENTIFICATION OF PROGNOSTIC FACTORS FOR MALIGNANT TRANSFORMATION IN PERSONS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OBSERVED IN THE CZECH REPUBLIC
- Nízkodávkovaný thalidomid v léčbě mnohočetného myelomu: stejná účinnost, nižší toxicita
- Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]
- PROGNOSTIC INFLUENCE OF ELEVATED PRETRANSPLANT SERUM FERRITIN ON THE RESULTS AFTER ALLOGENIC HEMATOPOETIC STEM CELL TRANSPLANTATION
- Registry of Monoclonal Gammopathies (RMG) in the Czech Republic
- Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group
- THE SIGNIFICANCE OF TWO DIFFERENT FREE LIGHT CHAIN IMMUNOASSAYS FOR MONITORING OF DISEASE ACTIVITY IN MULTIPLE MYELOMA PATIENTS
